Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The Phase IIb trial investigated the safety and efficacy of the JNJ-4178 regimen, which includes odalasvir, AL-335 and Olysio.
Highlights from research presented at the 52nd International Liver Congress in Amsterdam
The joint venture between the two companies will push the three-drug Olysio/odalasvir/AL-335 into further development.
Achillion has released new data showing excellent results from six weeks of treatment with company’s odalasvir and Gilead’s sofosbuvir.
ACH-3102, a hepatitis C drug under development by Achillion Pharmaceuticals, has received Fast Track status from the FDA, according to an...
The FDA has assigned the Fast Track designation to Achillion Pharmaceuticals, Inc.’s ACH-1625
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.